Current Status, Challenges, and Future Directions in Crohn’s Disease-Reference-Cited by-同舟云学术

Current Status, Challenges, and Future Directions in Crohn’s Disease

Published:2024-08-10 Issue:16 Volume:13 Page:4699
ISSN:2077-0383
Container-title:Journal of Clinical Medicine
language:en
Short-container-title:JCM

Author:

Selinger Christian¹^ORCID,van der Meulen Andrea²

Affiliation:

1. Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, St James University Hospital, 4th Floor Bexley Wing, Beckett Street, Leeds LS9 7TF, UK

2. Department of Gastroenterology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

Abstract

The treatment goal for patients with Crohn’s disease (CD) has traditionally been aimed at symptomatic steroid-free clinical remission [...]

Publisher

MDPI AG

Link

https://www.mdpi.com/2077-0383/13/16/4699/pdf

Reference10 articles.

1. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults;Lamb;Gut,2019

2. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD;Turner;Gastroenterology,2021

3. Gordon, H., Minozzi, S., Kopylov, U., Verstockt, B., Chaparro, M., Buskens, C., Warusavitarne, J., Agrawal, M., Allocca, M., and Atreya, R. (2024). ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J. Crohn’s Colitis, jjae091.

4. To STRIDE or not to STRIDE: A critique of “treat to target” in Crohn s disease;Herrlinger;Expert Rev. Gastroenterol. Hepatol.,2023

5. West, J., Tan, K., Devi, J., Macrae, F., Christensen, B., and Segal, J.P. (2023). Benefits and Challenges of Treat-to-Target in Inflammatory Bowel Disease. J. Clin. Med., 12.